Cargando…
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
AIM: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi(®)) was approved in the US to treat adults with PV. The purpose of thi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690394/ https://www.ncbi.nlm.nih.gov/pubmed/37531245 http://dx.doi.org/10.57264/cer-2023-0066 |
_version_ | 1785152516671930368 |
---|---|
author | Gerds, Aaron T Castro, Claudia Snopek, Frank Flynn, Megan M Ellis, Alexandra G Manning, Meredith Urbanski, Ray |
author_facet | Gerds, Aaron T Castro, Claudia Snopek, Frank Flynn, Megan M Ellis, Alexandra G Manning, Meredith Urbanski, Ray |
author_sort | Gerds, Aaron T |
collection | PubMed |
description | AIM: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi(®)) was approved in the US to treat adults with PV. The purpose of this study is to estimate the cost–effectiveness of ropeginterferon alfa-2b-njft, used as a first- or second-line treatment, for the treatment of patients with PV in the US. MATERIALS & METHODS: A Markov cohort model was developed from the healthcare system perspective in the United States. Model inputs were informed by the PROUD-PV and CONTINUATION-PV studies and published literature. The model population included both low-risk and high-risk patients with PV. The model compared ropeginterferon alfa-2b-njft used either as first- or second-line versus an alternative treatment pathway of first-line hydroxyurea followed by ruxolitinib. RESULTS: Over the modeled lifetime, ropeginterferon alfa-2b-njft provided an additional 0.4 higher quality-adjusted life years (QALYs) and 0.4 life-years with an added cost of USD60,175, resulting in a cost per QALY of USD141,783. The model was sensitive to treatment costs, the percentage of patients who discontinue hydroxyurea, the percentage of ropeginterferon alfa-2b-njft users who switch to monthly dosing, the percentage of ropeginterferon alfa-2b-njft users as 2nd line treatment, and the treatment response rates. A younger patient age at baseline and a higher percentage of patients with low-risk disease improved the cost–effectiveness of ropeginterferon alfa-2b-njft. CONCLUSION: Ropeginterferon alfa-2b-njft is a cost-effective treatment option for a broad range of patients with PV, including both low- and high-risk patients and patients with and without prior cytoreductive treatment with hydroxyurea. |
format | Online Article Text |
id | pubmed-10690394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Becaris Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-106903942023-12-02 Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera Gerds, Aaron T Castro, Claudia Snopek, Frank Flynn, Megan M Ellis, Alexandra G Manning, Meredith Urbanski, Ray J Comp Eff Res Research Article AIM: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi(®)) was approved in the US to treat adults with PV. The purpose of this study is to estimate the cost–effectiveness of ropeginterferon alfa-2b-njft, used as a first- or second-line treatment, for the treatment of patients with PV in the US. MATERIALS & METHODS: A Markov cohort model was developed from the healthcare system perspective in the United States. Model inputs were informed by the PROUD-PV and CONTINUATION-PV studies and published literature. The model population included both low-risk and high-risk patients with PV. The model compared ropeginterferon alfa-2b-njft used either as first- or second-line versus an alternative treatment pathway of first-line hydroxyurea followed by ruxolitinib. RESULTS: Over the modeled lifetime, ropeginterferon alfa-2b-njft provided an additional 0.4 higher quality-adjusted life years (QALYs) and 0.4 life-years with an added cost of USD60,175, resulting in a cost per QALY of USD141,783. The model was sensitive to treatment costs, the percentage of patients who discontinue hydroxyurea, the percentage of ropeginterferon alfa-2b-njft users who switch to monthly dosing, the percentage of ropeginterferon alfa-2b-njft users as 2nd line treatment, and the treatment response rates. A younger patient age at baseline and a higher percentage of patients with low-risk disease improved the cost–effectiveness of ropeginterferon alfa-2b-njft. CONCLUSION: Ropeginterferon alfa-2b-njft is a cost-effective treatment option for a broad range of patients with PV, including both low- and high-risk patients and patients with and without prior cytoreductive treatment with hydroxyurea. Becaris Publishing Ltd 2023-08-02 /pmc/articles/PMC10690394/ /pubmed/37531245 http://dx.doi.org/10.57264/cer-2023-0066 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Research Article Gerds, Aaron T Castro, Claudia Snopek, Frank Flynn, Megan M Ellis, Alexandra G Manning, Meredith Urbanski, Ray Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera |
title | Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera |
title_full | Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera |
title_fullStr | Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera |
title_full_unstemmed | Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera |
title_short | Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera |
title_sort | cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690394/ https://www.ncbi.nlm.nih.gov/pubmed/37531245 http://dx.doi.org/10.57264/cer-2023-0066 |
work_keys_str_mv | AT gerdsaaront costeffectivenessofropeginterferonalfa2bnjftforthetreatmentofpolycythemiavera AT castroclaudia costeffectivenessofropeginterferonalfa2bnjftforthetreatmentofpolycythemiavera AT snopekfrank costeffectivenessofropeginterferonalfa2bnjftforthetreatmentofpolycythemiavera AT flynnmeganm costeffectivenessofropeginterferonalfa2bnjftforthetreatmentofpolycythemiavera AT ellisalexandrag costeffectivenessofropeginterferonalfa2bnjftforthetreatmentofpolycythemiavera AT manningmeredith costeffectivenessofropeginterferonalfa2bnjftforthetreatmentofpolycythemiavera AT urbanskiray costeffectivenessofropeginterferonalfa2bnjftforthetreatmentofpolycythemiavera |